Product Name :
Tibenelast sodium
Description:
Tibenelast sodium is a phosphodiesterase inhibitor.
CAS:
105102-18-9
Molecular Weight:
288.29
Formula:
C13H13NaO4S
Chemical Name:
sodium 5,6-diethoxy-1-benzothiophene-2-carboxylate
Smiles :
[Na+].CCOC1C=C2SC(=CC2=CC=1OCC)C([O-])=O
InChiKey:
ILEWAUWOUIHKID-UHFFFAOYSA-M
InChi :
InChI=1S/C13H14O4S.Na/c1-3-16-9-5-8-6-12(13(14)15)18-11(8)7-10(9)17-4-2;/h5-7H,3-4H2,1-2H3,(H,14,15);/q;+1/p-1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Tibenelast sodium is a phosphodiesterase inhibitor.|Product information|CAS Number: 105102-18-9|Molecular Weight: 288.29|Formula: C13H13NaO4S|Chemical Name: sodium 5,6-diethoxy-1-benzothiophene-2-carboxylate|Smiles: [Na+].OPC 4392 Protocol CCOC1C=C2SC(=CC2=CC=1OCC)C([O-])=O|InChiKey: ILEWAUWOUIHKID-UHFFFAOYSA-M|InChi: InChI=1S/C13H14O4S.Atorvastatin MedChemExpress Na/c1-3-16-9-5-8-6-12(13(14)15)18-11(8)7-10(9)17-4-2;/h5-7H,3-4H2,1-2H3,(H,14,15);/q;+1/p-1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 50 mg/mL (173.PMID:33000406 44 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|The effect of the phosphodiesterase inhibitor Tibenelast, and placebo on isoproterenol-induced changes in heart rate, cAMP and norepinephrine levels in normal male volunteers is studied. Tibenelast increases the heart rate response to isoproterenol infusion, whereas norepinephrine and cAMP levels are not different in any treatment.|In Vivo:|Tibenelast is a potent orally active compound against anaphylactic shock induced by high dose antigen aerosol. When a lower aerosol challenge (0.05 mg/mL) is employed, bronchoconstriction is observed with a concomitant increase in lung resistance (RL) and a fall in dynamic compliance (Cdyn). Tibenelast at 25 mg/kg p.o. prevents these changes. Tibenelast is 10 times more potent than Aminophylline by i.v. administration; normalization of pulmonary function is achieved at 1 mg/kg i.v. Tibenelast is synergistic with epinephrine. The oral dose response curve of Tibenelast is enhanced with the co-administration of epinephrine. Tibenelast may be of significant value in the treatment of asthma and other respiratory diseases.|Products are for research use only. Not for human use.|
